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ORIGINAL ARTICLE
The prognosis of heart failure due to left ventric-
ular dysfunction is poor, with a 5-year survival of
50% and 10-year survival of only 20%.1 Specialist
heart failure nurse-led home-based management
not only improves quality of life and reduces
readmissions in patients with congestive heart fail-
ure, but also reduces costs and improves the effi-
ciency of the health care system.2–7 A combination
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of clinic- and home-based intervention has also
been reported to reduce recurrent readmission
and improve event-free survival.8 The economic
effect of such a system remains unknown, so this
prospective study was conducted to assess this
issue.
Methods
Patients
Patients with heart failure manifestations (ex-
erted breathing sensation, shortness of breath,
leg edema, fluid retention) and impaired left ven-
tricular contractility (left ventricular ejection frac-
tion ≤ 40% by echocardiography or Tc99m left
ventriculography) were enrolled in this study.
Gender, age, medications, serum biochemical
data, and etiologies of heart failure were recorded.
Patients were initially followed up at outpatient
department (OPD) at 4-week intervals. The man-
agement of these heart failure patients was ac-
cording to ACC/AHA guidelines for heart failure
management.9 Specialist nurse-led telephone vis-
iting was done at 2-week intervals. After their
conditions stabilized, patients were followed up
at OPD at 2- or 3-month intervals and received
telephone visiting at 3- or 4-week intervals. If the
patient was admitted to ward or visited the emer-
gency station (ES), the specialist nurse would care
for the patient and inform the attending visiting
staff. After discharge from the hospital, the pa-
tient would be scheduled to visit the OPD within
1 week.
Role of specialist nurse and telephone visiting
The specialist nurse did the history taking and
physical examination when the patient visited
the OPD. They recorded the vital signs and body
weight. The specialist nurse also gave the patient
health education about the pathophysiology of
heart failure, diet therapy, and limitation of fluid
intake. The specialist nurse-led telephone visit-
ing included body weight status, urine output,
compliance of medication, fluid intake, and side
effects of medication. If the symptoms and signs
of heart failure (exerted breathing sensation,
shortness of breath, leg edema, fluid retention)
or fluid retention up to 1.5–2 kg/week developed,
then the specialist nurse would arrange for the 
patient to visit the ES or be admitted after discus-
sion with the physician. The patient could com-
municate with the specialist nurse any time when
their condition changed. After discharge from the
hospital, the specialist nurse would communicate
with the patient within 48–72 hours.
Economic analysis of management for 
heart failure
The economic analysis was based on three
divisions including OPD, ES, and ward. The fre-
tquency of visiting OPD and insurance paymen
for visiting OPD were calculated. The frequencies
gof visiting ES and insurance payment for visitin
ES were calculated. The frequency of admission
to intensive care unit (ICU) and duration of ICU
stay were calculated. The admission rate, dura-
rtion of admission, and insurance payment fo
admission were calculated. The readmission rate
(caused by either heart failure or other etiolo-
gies) and mortality rate were also calculated.
These data were calculated half a year before
enrollment as control group. The exchange rate
between New Taiwan dollar (NT$) and United
States dollar on September 30, 2005 was US$1 =
NT$33.21.
Statistical analysis
Data were expressed as mean ± standard deviation.
Comparisons between groups for continuous data
were made using pair t test. Differences between
proportions were assessed by χ2 test. Multiple
regression analysis was conducted for the mean
duration of hospital stay, admission rate, and read-
mission rate due to etiologies other tthan hear
failure (such as infection, gastrointestinal bleed-
ting, etc.). All other variables, including enrollmen
to this program, age, gender, different comorbidi-
ties, and initial functional class t(New York Hear
Association) were used as the covariates. A value
of p < 0.05 was considered to indicate statistical
significance.
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Results
Patient characteristics
A total of 247 patients (168 males, 79 females;
mean age, 60±17 years) were enrolled. The etiolo-
gies for heart failure and medications are listed in
Table 1. The comorbidities are listed in Table 2. The
mean follow-up period was 139 ± 96 days. The
mean left ventricular ejection fraction was 35%.
Mortality during the follow-up period was 5.7%.
The mean functional class improved from 2.27 ±
0.80 to 1.96 ± 0.90 (Table 3, p < 0.001). There were
10 patients (48%) with initial functional class IV
that improved to functional class I (one patient),
functional class II (six patients), and functional
class III (three patients).
Specialist nurse-led telephone visiting
There were 1618 times of specialist nurse-led
telephone visiting (average 8 ± 6 times/patient).
Average time spent on each telephone visit was
4.3 ± 3.0 minutes. The telephone numbers for pa-
tient consultation were 266 times. The compliance
for patient follow-up was 97.4%.
Economic burden of admission and ES 
Before enrollment, the total admission fees were
tUS$624,020 (Table 4). After enrollment, the cos
was reduced to US$362,722 (41.8% reduction).
The total numbers of admission were reduced 36
times (33.0% decrement). The reduction of each
admission cost was US$8166. The mean duration
of hospital stay due to heart failure was reduced
from 19.5 ± 21.7 to 14.3 ± 17.7 days (p = 0.039;
Figure 1). The readmission rate due to heart failure
rwas 16.5% (before enrollment) and 17.0% (afte
enrollment). After enrollment, the readmission
f fClinic- and home-based intervention o  heart ailure
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Table 1. Patient characteristics
Sex (male/female), n 169/78
Age (yr) 60 ± 17
Mean left ventricular ejection 35
fraction (%)
Medications, n (%)
Digoxin 144 (63)
β-blocker 108 (47)
ACEI and/or ARB 115 (61)
Diuretics 203 (89)
Anti-arrhythmic agent 69 (30)
Etiologies for heart failure, n (%)
Coronary artery disease 120 (48.6)
Dilated cardiomyopathy 70 (28.3)
Valvular heart disease 37 (15.0)
Myocarditis 10 (4.0)
Others* 14 (5.7)
*Including congenital heart disease and cardiomyopathy other than
dilated or ischemic types. ACEI = angiotensin converting enzyme
inhibitor; ARB = angiotensin receptor blocker.
Table 2. Concomitant associated diseases
Concomitant associated disease n (%)
Hypertension 92 (37)
Diabetes mellitus 79 (32)
Atrial fibrillation 72 (29)
Hyperlipidemia 52 (21)
ASD 3 (1)
VSD 3 (1)
Stroke 20 (8)
Chronic renal insufficiency 36 (15)
Uremia 14 (6)
Liver cirrhosis 5 (2)
COPD 17 (7)
Multiple comorbidities
1 disease 66 (26.7)
2 diseases 63 (25.5)
3 diseases 42 (17.0)
4 diseases 16 (6.5)
5 diseases 2 (0.8)
6 diseases 1 (0.4)
ASD = atrial septal defect; VSD = ventricular septal defect; COPD =
chronic obstructive pulmonary disease.
Table 3. New York Heart Association functional class
Functional Before enrollment, After enrollment,
classification n (%) n (%)
Class I 34 (14) 82 (33)
Class II 132 (53) 112 (45)
Class III 60 (24) 31 (13)
Class IV 21 (9) 22 (9)
rate due to etiologies other than heart failure
(such as infection, gastrointestinal bleeding, etc.)
was reduced from 15.9% to 7.7%.
Multiple regression analysis was conducted
for the mean duration of hospital stay, admission
rate, and readmission rate due to etiologies other
than heart failure (such as infection, gastroin-
testinal bleeding, etc.). Initial functional class 
(β coefficient = 0.51; p < 0.001) and enrollment
to this program (β coefficient = −0.17; p = 0.015)
showed statistical significance for the mean dura-
tion of hospital stay. Only initial functional class
(β coefficient = 0.183; p = 0.03) showed statistical
significance for admission rate. However, both ini-
tial functional class (β coefficient = 0.31; p < 0.001)
and enrollment to this program (β coefficient =
−0.37; p < 0.001) showed statistical significance
rfor the readmission rate due to etiologies othe
than heart failure.
The total numbers of visiting ES were reduced
(from 43 to 27 times, 37.2% reduction). The
average fees of visiting ES were US$152 ± 92 and
US$226±156 (before vs. after enrollment; p=0.02;
Figure 2). The total fees of visiting ES were reduced
from NT$6528 to NT$6101 (6.5% decrement).
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Table 4. Changes of heart failure patients before and after enrollment (n = 247)
Before enrollment After enrollment Change (%)
Cost (US$)
Total admission 624,020 362,722 −41.8
Non-heart failure admission 541,800 184,136 −66.0
ES 6528 6101 −6.5
OPD 90,783 94,855 4.4
Duration (d)
Total admission 2127 1042 −51.0
Non-heart failure admission 1729 556 −67.8
ES 66 45 −31.8
ICU 327 160 −51.1
Numbers
Total admission 109 73 −33.0
Non-heart failure admission 82 26 −68.3
ES 43 27 −37.2
ICU 35 12 −65.7
OPD 1085 1352 24.6
ES = emergency station; OPD = outpatient department; ICU = intensive care unit.
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Economic burden of OPD (Figure 3)
The frequency of visiting OPD increased from
5.2 ± 3.2 to 6.6 ± 4.1 times/patient (p < 0.001).
The total numbers of visiting OPD also increased
from 1085 to 1352 times (24.6% increment). The
mean fee of visiting OPD was reduced from
US$84 ± 84 to US$70 ± 62 (p < 0.001). The total
fees of visiting OPD increased from US$90,783 to
US$94,855 (4.4% increment).
Discussion
The management of heart failure consumes
1–2% of health care expenditure in European
countries,10,11 with around 75% relating to in-
patient care. In 2000, 1.5% of total health care
expenditure was attributed to chronic heart fail-
ure in the United States, and 65% of heart failure 
expenditure was related to hospitalization.12 About
45% of patients hospitalized with acute heart
failure will be rehospitalized at least once (and
15% at least twice) within 12 months.13,14 There-
fore, reduction of admission also reduces the eco-
nomic burden of heart failure. In this study, the
admission cost was reduced 41.8% by a clinic-
and home-based intervention of heart failure.
tThis is similar to the 40.3% reduction in recurren
bed utilization reported by Stewart et al.2 The 
reduction of each admission cost was US$8166.
This is also similar to the report of estimated
savings in hospital readmission costs of $9800/
patient.6 In this study, the mean duration of hos-
pital stay due to heart failure and unplanned ad-
mission was also reduced. The data were rsimila
to the report of Thompson et al.8 Via bidirec-
tional communication between medical staff and
patients, a clinic- and home-based intervention
program can improve survival and self-care behav-
ior in patients with heart failure as well as reduce
the number of events, readmissions, and days in
hospital.
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There are several possible reasons for the favor-
able economic outcome of such management. This
clinic- and home-based intervention of heart fail-
ure patients was associated with good compliance
of β-blocker therapy (47%) during follow-up.8
A similar finding was reported by Thompson et al
and there was 56% of β-blocker use in their
study.8 Patients’ knowledge and β-blocker treat-
ment improve prognosis of patients from a heart
failure clinic.15 This clinic- and home-based inter-
vention of heart failure improved patients’ knowl-
edge of heart failure and increased compliance
with β-blocker therapy. Cost-effectiveness studies
also suggest that β-blockers for heart failure 
are cost-saving over a period of approximately 
6 months.16,17 On the other hand, angiotensin-
converting enzyme inhibitors are a mainstay of
treatment in patients who can tolerate them; in
patients who cannot take these drugs, angiotensin
II receptor blocking agents offer an alternative.
Both medications improve functional status and
survival in heart failure patients. With good com-
pliance to both medications, the New York Heart
Association functional class improved in this study.
Improvement in functional status and exercise
capacity has also been reported by West et al.18
This improvement reduced the readmission of
heart failure patients.
In this study, the total number of OPD visits in-
creased by 24.6%, but the average fees of visiting
OPD were significantly reduced. The total OPD
fees only increased 4.4%. On the other hand, the
total number of ES visits decreased by 37.2% and
the total fees of visiting ES decreased by 6.5%. Any
intervention capable of decreasing even a small
fraction of the adverse outcome, most notably hos-
pital admission and length of stay, could trigger
significant cost savings in the management of heart
failure.12
There were several study limitations. First, there
were no reference patients for comparison and
this study was not a randomized controlled trial.
Second, some patients had been treated by cardi-
ologists before enrollment. Thus, the improvement
in clinical and economic parameters may partially
be affected by previous therapeutic modalities.
Therefore, a longer period of time is needed to eval-
uate the cost-effectiveness of the clinic- and home-
based intervention for patients with heart failure.
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